William Blair analyst Lachlan Hanbury Brown has maintained their bullish stance on OCUL stock, giving a Buy rating yesterday.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Lachlan Hanbury Brown has given his Buy rating due to a combination of factors related to Ocular Therapeutix’s promising clinical trial progress and strategic decisions. The company’s SOL-1 trial has shown exceptional retention and adherence to protocol, with rescue injections aligning with management’s expectations. This consistency is a positive indicator for the trial’s success, with top-line data anticipated in the first quarter of 2026.
Additionally, the strategic decision to modify the rescue criteria in the SOL-R trial to better reflect real-world practices is seen as a move that could facilitate easier adoption in the commercial market, should the treatment receive approval. The introduction of a long-term open-label extension study for both SOL trials is expected to provide valuable insights into the long-term safety and efficacy of the treatment, potentially demonstrating the benefits of early intervention. These factors collectively contribute to the optimistic outlook and the Buy rating for Ocular Therapeutix’s stock.
In another report released yesterday, Needham also maintained a Buy rating on the stock with a $15.00 price target.
Based on the recent corporate insider activity of 32 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of OCUL in relation to earlier this year.